Liver Failure represents a $15 billion market. There is no truly effective cure for liver failure, and current solutions such as transplantation have some major drawbacks, with only one liver available for every four people on the transplant waiting list, highlighting a major unmet need.
We have demonstrated the efficacy of PMSC-II, a “repair cell”, and PPCH-01, liver progenitor cells, on preclinical models. We plan to file IND applications with the FDA for both therapies within several months and complete Phase I/II clinical trials in 2025.